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Purpose of the study
In Vietnam, treatment failure to first-line ART, and the
decision to switch patients to second-line ART, is usually
made on the basis of clinical and immunological criteria
because viral load (VL) testing has just been performed
since June 2007. However, many studies have shown that
these criteria have very low sensitivity and specificity. We
estimated the rate of virological failure (VF), and predic-
tors in HIV patients with clinical and/or immunological
failure to first-line regimens in Ho Chi Minh City.
Methods
Between June and December 2007, VL testing was com-
pleted on 248 patients with MOH clinical (new WHO
stage 3 or 4 condition) or immunological criteria (CD4
fall to below pre-treatment value or <50% of highest on-
treatment value), additional WHO criteria (CD4<100
after 12 months on ART), or history of previous subopti-
mal ARV regimens (mono- or dual-therapy or inadequate
doses). Viral load testing was done at Pasteur Institute
(RT-PCR Promega, DTCS Beckman Coulter).
Summary of results
177 patients (71.4%) were male. Median age was 27 years
(IQR: 9–32). Twenty-four (9.7%) had clinical failure, 205
(82.7%) with immunological criteria, 41 (16.5%) with
previous suboptimal treatment. Eighty-seven (35.8%)
patients had previous ART. Median duration of ART was
14.5 months (IQR: 11–17). Median baseline CD4 was
low (53 cells/ml; 20–126). Median CD4 change after 12
months was 35 (-12–86). Most of patients were on first-
line regimens: 82 (33.2%) on D4T+3TC+NVP, 75
(30.4%) on D4T+3TC+EFV, 26 (10.5%) on
AZT+3TC+NVP, and 21(8.5%) on AZT+3TC+EFV.
Overall, the rate of VF was 58.5%, highest in patients with
both previous suboptimal treatment and immunological
failure (91%), and lower in those with only previous sub-
optimal treatment (80%). Only clinical or immunological
failures had lowest rates of VF (57.1% and 57.0%). Viro-
logical failure was independently associated with age > 25
years(OR: 7.1, 95% CI: 2.6–19.3), male (4.3;1.7–10.4),
CD4 > 50 (1.7; 0.8–3.6), history of pre-ART (4.0; 1.8–
8.9), duration of ART > 12 months (4.2; 1.7–10.1), and
CD4 increase <50 after 12 months of treatment (4.7; 2.2–
10.1).
Conclusion
Immunological and clinical failures predicted VF in only
57% and may lead to unnecessary ART change in 41.5%
of patients. VL testing should be done to assess response
of ARV treatment. Moreover, patients with virological sup-
pression on first-line ARV also benefit by prolonging the
use of first-line drugs and thereby preserving future treat-
ment options.
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